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Abstract
Presently, orthopedic and oral/maxillofacial implants represent a combined $2.8 billion market, a
figure expected to experience significant and continued growth. Although traditional permanent
implants have been proved clinically efficacious, they are also associated with several drawbacks,
including secondary revision and removal surgeries. Non-permanent, biodegradable implants offer
a promising alternative for patients, as they provide temporary support and degrade at a rate
matching tissue formation, and thus, eliminate the need for secondary surgeries. These implants
have been in clinical use for nearly 25 years, competing directly with, or maybe even exceeding,
the performance of permanent implants. The initial implantation of biodegradable materials, as
with permanent materials, mounts an acute host inflammatory response. Over time, the implant
degradation profile and possible degradation product toxicity mediate long-term biodegradable
implant-induced inflammation. However, unlike permanent implants, this inflammation is likely to
cease once the material disappears. Implant-mediated inflammation is a critical determinant for
implant success. Thus, for the development of a proactive biodegradable implant that has the
ability to promote optimal bone regeneration and minimal detrimental inflammation, a thorough
understanding of short- and long-term inflammatory events is required. Here, we discuss an array
of biodegradable orthopedic implants, their associated short- and long- term inflammatory effects,
and methods to mediate these inflammatory events.
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I. INTRODUCTION
The search for a promising alternative for the replacement or functional restoration of
damaged bone tissues has largely pointed to biodegradable implants.1 The concept of
biodegradable implants was introduced by Kulkarni et al. in the late 1960s. Subsequently,
the first usage of these materials in orthopedic surgery was completed by Rokkanento to
treat ankle fractures in 1984 with internal fixation devices.2–4 Over the past three decades,
the number of biodegradable implants in clinical use has significantly increased, which
includes cylinder rods, plates, screws, tacks, suture anchors, mesh, plugs, wires, arrows, and
drug delivery devices.2
Biodegradable implants offer a number of financial, psychological, and clinical advantages
over permanent metal implants.5 They provide the appropriate amount of mechanical
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strength when necessary, and degrade at a rate similar to new tissue formation, thereby
transferring the load safely to the healed bone and eliminating the need for an additional
revision and removal operation.6 Of note, the added expense of metallic implant removal,
which occurs 19 to 54% of the time depending on the fracture type, makes resorbable
implants more cost-effective by approximately seven hundred dollars less per metallic
implant.7 Permanent implants, which include metallic (ie, stainless steel, cobalt-chromium,
and titanium alloys) and non-degradable plastic (ie, polyethylene and polyurethane)
implants, are often cited as being too strong or stiff for optimal bone healing as well as
creating stress shielding.8 In addition, metal implants are often removed, either after the
healing process is complete, or due to complications such as the accumulation of metals in
tissues,9,10 growth restriction,11 pain,12 and/or implant migration.13
An astonishing number, over 90%, of patients in a perception prospective study conducted
by Mittal et al. considered revision and removal surgeries to be the largest drawback of
metal implants.2 The avoidance of removal surgeries, as seen with biodegradable implants,
is highly appreciated by patients, since it results in decreased patient costs, recovery time,
and time off from work. Biodegradable implants may also present less long-term
inflammation since their stay in the body is only temporary, as compared to permanent
implants. Additionally, the patient will not have to experience the added trauma from these
surgeries, therefore reducing the physiological impact and stress on the patient and their
family. For health-care providers, reduced financial costs via more efficient use of
healthcare resources and surgeon time results in an increased number of possible patients
that may be treated.7 From a clinical point of view, biodegradable implants result in
decreased stress shielding,14 and a lack of interference with imaging techniques. There have
even been positive results reported on the use of biodegradable screws and pins in
ankles.15–19
In addition to serving as fracture fixations and stabilization devices, biodegradable matrices
with appropriate pore size and interconnectivity are used to promote the regeneration of
engineered bone tissue.. Bone defect repair utilizing tissue engineering strategies has been a
rapidly growing field of research.20,21 Biodegradable implants and porous matrices may also
be used as drug releasing devices. For instance, these implants encapsulated with growth
factors and antibiotics have potential to accelerate healing processes and prevent chronic
bone infections, respectively.22
Although biodegradable implants overcome inherent disadvantages of permanent metal
implants, they are also associated with various shortcomings. Long-term performance of the
biodegradable implant is largely determined by the inflammatory events at the implant-host
tissue interface,23 and their degradation profiles. The following is a review of the advances
that have been made in understanding the acute and chronic inflammatory events at the
implant-host tissue interface and the developing methods for controlling these events. A
thorough understanding of the body’s response at the bone-implant interface is crucial for
the development of proactive implants that promote optimal outcomes for patients.24
II. BIODEGRADABLE ORTHOPEDIC IMPLANTS
The concept of biodegradable implants came into existence through the discovery of sutures
that resorb in the body.25,26 Based on the success of biodegradable sutures, many
biodegradable implants were designed for various clinical needs. For centuries, metals,
metal alloys, and non-degradable plastics have dominated the field of orthopedic implants.
However, due to the problems associated with permanent implants, the quest for
biodegradable implants has been intensified resulting in a number of biodegradable implants
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for orthopedic use.27,28 In the last few years, the number of FDA-approved biodegradable
orthopedic implants and the market for these products have shown tremendous growth.29
II.A. Types of Biodegradable Materials
Biodegradable polymers are also known as bioresorbable or bioabsorbable polymers. These
polymers can be synthetic or natural and degrade through hydrolysis/enzymatic degradation.
According to the literature, polyglycolide (PGA) was the first biodegradable polymer known
to the device community.26 Since then, researchers have developed a wide variety of
biodegradable polymer groups such as poly(α-esters), polyphosphazenes, and
polyurethanes.30,31 Among them, the poly(α-esters) group, which includes polyglycolide
(PGA), polylactide (PLLA), and their co-polymer poly(lactide-co-glycolide) (PLGA), have
attracted much attention by the orthopedic device community, due to their excellent
biocompatibility and tunable physical and degradation properties. Polymers such as
polydioxanone (PDO), polycaprolactone (PCL), polyhydroxybutyrate (PHB), and
polyhydroxyvalerate (PHV) have also been accepted for use in orthopedic devices. In
addition to synthetic polymers, researchers are also developing implants utilizing
biopolymers such as collagen, elastin, and hyaluronic acid, as well as natural polymers such
as chitosan, silk, and starch. Further, the synthetic and natural polymers have been combined
with nano-hydroxyapatite (nano-HAP) or tri-calcium phosphate (TCP) to design orthopedic
implants that have bone-like composition. A list of synthetic and natural polymers and their
composites that have been developed into orthopedic implants is presented in Table 1.
II.B. Biodegradable Implants
A number of polymers, mainly poly(α-esters), have been fabricated into various orthopedic
devices for fracture fixation, interference fixation, and meniscal repair. Devices such as
screws, plates, rods, staples, and tacks, are currently being used in orthopedic, maxillofacial,
and spine surgery applications (Fig. 1).28,29,32 In addition, scaffolds for bone tissue
engineering, and cements and gels for bone defect filling are currently under development.33
A large amount of clinical data is now available on biodegradable implants, mainly screws.
The data suggests that in a majority of the cases the implants fulfill the clinical need,
however, the long-term follow-up studies have shown some adverse effects (Table 1).
Biodegradable implants and the possible short-term and long-term foreign body reactions
are reviewed in the following sections.
III. SHORT-TERM EVENTS OF BIODEGRADABLE IMPLANT-ASSOCIATED
FOREIGN BODY REACTIONS
III.A. Onset of Foreign Body Reaction
Surgical implantation of a biomaterial, regardless of its being inert and nontoxic, will initiate
the on-set of a foreign body reaction (FBR).34 It has been established that the combination
of two events is the key player in triggering an inflammatory cascade by the host -- the
immediate adsorption and binding of blood plasma proteins and other molecules onto the
biomaterial’s surface, as well as the injury of the micro-vasculature and tissue during
implantation and the associated histamine release by local mast cells. The mechanisms by
which surface- absorbed proteins modulate the progression of FBR, including leukocyte
recruitment, differentiation into foreign body giant cells (FBGCs), and cytokine and matrix
metalloproteinases (MMPs) release, have been largely investigated and are illustrated in Fig.
2.
1. Biomaterial Surface Protein Adsorption—The protein layer that immediately
forms on the biomaterial upon implantation has been referred to as a ‘conditioning film.’35
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The ‘Vroman effect,’ first described about half a century ago, explains the competition,
rearrangements, and displacement of absorbed proteins that occurs at the biomaterial
surface.36,37 Small proteins adsorb first since they can be rapidly transported to the surface.
Then, gradually, they are replaced with larger proteins with higher affinity.23 After complex
processes of adsorption and desorption, an equilibrium is finally reached at the interface.38
This ‘conditioning film’ of proteins on the biomaterial has been proven to mediate host
tissue-implant interactions and initiate FBRs.35 Specifically, this protein film is recognized
by the integrin receptors present on neutrophils and macrophages, and thus, converts the
implant into a biologically recognizable material.39 It is important to note that the onset and
progression of the FBR is independent of whether the implant is permanent or
biodegradable, but dependent on the protein layer bound to the biomaterial’s surface.
Fibrinogen, albumin, complement fragments, and non-specific antibodies are among the
proteins that are absorbed on the biomaterial’s surface.40–42 It has been proved that
fibrinogen, unlike complement and immunoglobulin G, is essential for the host to mount an
inflammatory response to the implanted biomaterial. Animals unable to synthesize
complement and immunoglobulin G still experience an acute inflammatory response to
biomaterial implantation, with neutrophils and macrophages surrounding the biomaterial. On
the other hand, animals with low levels of fibrinogen require injections of fibrinogen to
mount an inflammatory response to the implanted biomaterial.43
Implant-bound fibrinogen interacts with macrophages via a macrophage integrin, Mac-1/
CD11b/CD18, and P1, a short sequence within the fibrinogen D domain.43,44 It has been
demonstrated that the absorption of fibrinogen to implant surfaces leads to the unmasking of
the P1 sequence and a second sequence, P2. Also, on the biomaterial surface, the P1 and P2
sites may be exposed via the coagulation cascade and undergo thrombin-mediated
conversion of fibrinogen to fibrin. Fibrin(ogen) P1 and P2 sites together interact with Mac-1
and allow for the binding of macrophages; and thus, they are directly related to the
recruitment of macrophages, and inflammatory response severity.41 Activated macrophages
release cytokines and chemokines, including IL-1, TNF-α, VEGF, monocyte
chemoattractant protein (MCP)-1, and IL-8, which in turn activate the proximal vasculature
and attract leukocytes and fibroblasts (Fig. 2).45 Soluble fibrinogen, unlike implant-absorbed
fibrinogen, does not have the P1 sequence exposed, and thus, is not pro-inflammatory.44
Implant-bound fibrinogen, via the GPIIb/IIIa integrin, may also bind to platelets. These cell
fragments contain α-granules, which are composed of several growth factors, such as
insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), and
transforming growth factor-β (TGF-β), and clotting proteins including thrombospondin,
fibronectin, and von Willebrand factor (vWF). The α-granules also express the adhesion
molecule P-selectin, which plays an essential role in the initial recruitment of leukocytes to
the site of injury during FBR.
The complement cascade may be triggered by two different pathways during the
implantation of a biomaterial, namely, via the alternative and classical complement
pathways (Fig. 2).46 The alternative complement pathway is activated with the spontaneous
adsorption of complement protein, C3b, onto the biomaterial’s surface. C3b may further
complex with complement factor Bb, resulting in the formation of C3b convertase (C3bBb),
which is responsible for the splicing of C3 into many C3a’s and C3b’s. Subsequently, this
leads to the release of C5a, a potent leukocyte chemoattractant. C3a and C5a are
anaphylatoxic peptides, and have been shown to increase the permeability of the capillary
bed, induce the release of histamine from mast cells, and increase monocyte/macrophage
activity.47 Furthermore, macrophages can recognize and bind to the absorbed C3b via CR1/
CD35 or CD11b/CD18 and CD11c/CD18 cell-membrane receptors. 40,48 On the other hand,
with a specific binding of antibodies to the implant surface, activation of the classical
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complement pathway may ensue. The Fc domain of these antibodies is recognized by
complement factor C1q, causing deposition and activation of C3b on the biomaterial,
resulting in a similar response as seen with spontaneously adsorbed C3b. Macrophages can
also recognize the Fc domain via Fc receptors, which upon stimulation cause the
macrophages to release pro-inflammatory cytokines, such as IL-1, IL-6, and TNFa,
furthering the FBR progression.40,45
2. Histamine Release by Local Mast Cells—Microvasculature and tissue damage
during implantation results in a histaminic response in the surrounding tissue.43 Tang et al.
demonstrated that histamine release by mast cells triggers the rapid migration of
inflammatory cells, such as neutrophils and monocytes, towards the implanted biomaterial,
and progression of a FBR.49 Specifically, mast cell degranulation and histamine release
causes hyperemia, enhanced expression of endothelial adhesion molecules (ie, P-selectin),
and subsequent migration of phagocytic cells through the endothelial barrier. Chemokines,
including macrophage inflammatory protein-1a (MIP-1a) and monocyte chemoattractant
protein-1 (MCP-1), direct phagocytic cells toward the biomaterial. Phagocytic cells adhere
to the implant surface through the binding sites on the adsorbed fibrinogen and Mac-1. The
importance of histamine in the progression of FBRs has been demonstrated as histamine
release is largely observed adjacent to subcutaneously implanted biomaterial. Furthermore,
the importance of histamine in the progression of FBRs has been demonstrated through the
inhibition of the H1 and H2 histamine receptors (ie, pyrilamine and famotidine,
respectively), which results in significantly lower numbers of neutrophils and macrophages
recruited to the site of implantation.41 Also, a congenital deficiency of mast cells results in a
decrease in inflammatory cells at intraperitoneal and subcutaneous implants; however, after
replenishing these animals with mast cells, a normal inflammatory response may be
observed upon implantation.49
III.B. Progression of Foreign Body Reaction
1. Leukocyte Extravasation—The homing of polymorphonuclear leukocytes (ie,
neutrophils) around the implanted biomaterial physically marks the beginning of an acute
inflammatory reaction.34,50 Neutrophils are stimulated by the histamine and pro-
inflammatory cytokines, such as IL-1β and TNF-α, released from mast cells. These signals
also stimulate the expression of vascular cell adhesion molecule (VCAM)-1, intercellular
adhesion molecule (ICAM)-1, and E-selectin on vascular endothelial cells.40 Increased
neutrophil-endothelial cell interaction, via the binding of endothelial cell adhesion molecules
and neutrophil ligands, results in the extravasation of neutrophils from the bloodstream.
Chemokines direct the neutrophils to the implantation site once they have left the
bloodstream, at which time they will degranulate and release pro-inflammatory mediators to
further enhance the recruitment of additional inflammatory cells. In addition to enhancing
the inflammatory response, neutrophils induce angiogenesis by the production of several
angiogenic factors, such as vascular endothelial growth factor (VEGF), also known as
vascular permeability factor (VPF). VEFG-induced neovascularization is believed to be
critical in the development of granulation tissue and successful engraftment of implanted
scaffolds into the host.50
2. Monocyte Recruitment and Differentiation into Macrophages—Inflammatory
monocytes and macrophages replace short-lived neutrophils by way of chemotaxis.34,40,51
Monocytes are recruited by the pro-inflammatory cytokines, such as monocyte chemotactic
protein-1 (MCP-1) and IL-6, which are released from the neutrophils and mast cells
surrounding the implant. 52 After adhering to the biomaterial, monocytes differentiate into
macrophages. Macrophages differ morphologically from monocytes as they have a greater
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cytoplasmic-to-nuclear area ratio and are more spread; however, they express both F4/80
and CD11b, demonstrating their monocytic lineage (Fig. 3a, b).52
The accumulation of macrophages is a phenomenon that has been specifically associated
with biodegradable implants.39 A dense layer of macrophages is commonly observed in the
first few weeks of implantation, as well as the end stage of the resorption process, which
depends on the degradation time of the specific biomaterial used.50 Changes in the
biomechanical and morphological properties of the degrading materials may significantly
intensify the FBR.
Numerous studies have identified macrophages to be the key cellular mediator of implant-
associated FBRs.52–60 Being ‘professional’ phagocytic cells, activated macrophages secrete
a large array of products, including proteolytic enzymes, free radicals, and reactive oxygen
species, in their attempt to degrade the implant. Also, macrophages secrete MMPs and tissue
inhibitor of metalloproteinases (TIMPs), which allow for wound healing and tissue
regeneration.53,54,61 As seen in Fig. 2, macrophages play a central role in a very complex
interaction involving a wide array of inflammatory cytokines, chemokines, growth factors,
and complement components, as well as numerous cell types, including other macrophages,
neutrophils, lymphocytes, endothelial cells, and fibroblasts. Though T and B lymphocytes
were originally thought to be the source of many cytokines during the FBRs, this notion has
been largely diminished as a result of several recent studies. For instance, T-cell-deficient
mice are able to develop a normal FBR with normal levels of IL-13 and IL-4.62 In addition,
Higgins et al. found that B- and T- cells are not in close proximity to the FBGCs and thus,
may not have significant direct cell-to-cell interactive effects (Fig. 3c, d, e). The presence of
only a few lymphocytes in the lesion area also suggests that the high levels of T-cell-
associated cytokines found in the lesion are from another source, most likely macrophage-
or neutrophil-derived.52
Macrophages can recognize biomaterials via several different pathways, as illustrated in Fig.
2. Upon implantation, adsorbed proteins, such as fibrinogen and fibronectin, may trigger
macrophage responses.48 Also, macrophages may bind with implant surface-adsorbed
immunoglobins and/or complement components.47 Lastly, the presence of active cytokines
and growth factors may allow for macrophage adhesion via ligand-receptor complexes. In
any event, macrophages bind to foreign materials via integrin-mediated adhesive
interactions. Integrins are heterodimeric transmembrane proteins and primary receptors,
which regulate cell adhesion to extracellular matrix (ECM) proteins, as well as intercellular
adhesive interactions. These integrin interactions are essential in regulating the functions of
macrophages, including rearrangement of the actin cytoskeleton, cell movement, activation
of specific cellular functions, gene transcription, cell proliferation and survival.53
Macrophages interact with many cell types that mediate the progression of the FBR via
cytokines (Fig. 2). For example, tumor necrosis factor-α (TNF-α) release is a potent
inflammatory cytokine that can activate virtually all cells, and is strongly implicated during
inflammation and tissue destruction.63 In addition, macrophages have been shown to interact
with neutrophils via interleukin-1β (IL-1β), IL-6, IL-8, IL-10, transforming growth factor-β
(TGF-β), TNF-α, macrophage inflammatory protein-1α (MIP-1α), and MIP-1β, which
results in neutrophil granulation and further cytokine release. Additionally, macrophages
have been linked to the clotting cascade through their interaction with platelets via platelet-
derived growth factor (PDGF), TGF-β, and β-fibroblast growth factor (β-FGF). Not only do
macrophages interact with the coagulation cascade, they also play a crucial role in
promoting angiogenesis via releasing IL-1, TGF-β, and PDGF to activate endothelial cells.
The release of PDGF also stimulates smooth muscle cells and fibroblasts, leading to the
formation of more mature vessels, and less ‘leaky’ vessels. Also, macrophages secrete
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numerous mediators that influence their own actions, such as IL-6, IL-10, IL-12, MCP -1,
-2, -3, -4, macrophage colony-stimulating factor (MCSF), MIP-1α, -1β, -1δ, -3, macrophage
migration inhibitory factor (MIF), and TGF-β. In respect to progression of the FBR,
macrophages have also been shown to secrete high levels of pro-inflammatory cytokines,
including IL-1β and IL-6, early upon biomaterial implantation.43 However, as time
progresses, the levels of pro-inflammatory cytokines diminish, and macrophages express
higher levels of anti-inflammatory IL-10, which may have a role in macrophage fusion, and
in the suppression of inflammatory responses during the FBR.52
Macrophages have been recently associated with fibrotic matrix formation via interacting
with fibroblasts that function in ECM production. A subpopulation of macrophages, referred
to as ‘matrix forming macrophages,’ may play an important role in synthesizing the
important component of the fibrotic capsule often found surrounding implants. 64
Muldashev et al. identified macrophages with an unusual structure not commonly seen in
macrophages --large vacuoles, Hale-positive cytoplasm, presence of the endo- and
exocytosis signs, and evidence of active metabolism. Staining positive in the Hale reaction
indicates these macrophages are degrading and fragmenting deposited collagen fiber, and
then subsequently releasing glycosaminoglycans. Thus, a possible mechanism explaining the
formation of the collagen matrix around implants involves fibroblasts synthesizing collagen
fibers, and matrix forming macrophages synthesizing the proteoglycan component.
3. Macrophages Differentiate into FBGCs—FBGCs are a morphologic variant of
macrophages, and form when the macrophages undergo “frustrated phagocytosis” and are
not effective at removing the biomaterial implant (Fig. 3a, b).54 Therefore, as the FBR
progresses, the percent of macrophage fusion into FBGCs increases, while cell number
surrounding the implants subsequently decreases (Fig. 3f, g). Encapsulation of the
biomaterial in a continuous sheet of large, highly multinucleated FBGCs has been proposed
as a protective mechanism to isolate the foreign object from the host. The walling-off
process by FBGC formation represents an acute phase, which will eventually result in a
relatively avascular, highly fibrous capsule that further limits the interaction of the foreign
material with the body.
FBGC formation occurs through IL-4 and IL-13 – induced fusion of macrophages,52 and
requires the expression of vitronectin,43,45 P2X7, CD98, SiRPaD44, and dendritic cell-
specific transmembrane protein (DC-STAMP).40 FBGCs are considered to be at the terminal
stage in the monocyte-macrophage differentiation system.53 FBGCs can contain anywhere
from three to a hundred nuclei, with their size depending on the intensity of the
inflammatory response. Fittingly, the number of FBGCs progressively decreases with time
as the biomaterial is degraded and the FBR is resolved.39
Unlike macrophages, FBGCs are poorly phagocytic; however, they exhibit higher
extracellular degradation capacity, and express high levels of lysosomes and respiratory
enzyme activities. 53,65–67 FBGCs can also secrete chemokines and cytokines to direct and/
or activate additional inflammatory and wound healing cells.63 Unlike macrophages, which
have been shown to be strongly linked to the fibrotic process and angiogenesis, Luttikhuizen
et al. demonstrated that FBGCs are not strongly involved in these two processes as they
exhibit only low levels of TGF-β, VEGF, and FGF expression.
Scientists have largely questioned whether the presence of FBGCs near an implant is just a
sign of biodegradability and a part of normal bone healing after the biomaterial
implantation, or actually a sign of insufficient biocompatibility, inflammation, and implant
failure. Nuss et al. have nicely outlined the arguments for both sides of this debate.39
Briefly, one may argue that FBGCs are not a sign of pathology and just a normal part of
Amini et al. Page 7
J Long Term Eff Med Implants. Author manuscript; available in PMC 2012 October 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
bone healing after biomaterial implantation since (i) FBGCs mediate the resorption of
biodegradable materials, (ii) their presence does not impair bone formation, and (iii) their
presence indicates low degradability of the implant. On the other hand, FBGCs may be a
sign of pathology (ie, insufficient biocompatibility and implant failure) as (i) the fusion of
macrophages is induced by poorly tolerated foreign bodies, (ii) the presence of FBGCs is
associated with structural and functional failure of the implant, and (iii) FBGCs seem to
concentrate the phagocytic and degradative activities at the tissue-material interface and,
therefore, are responsible for the damage and failure of the implant.
More likely, we believe FBGCs are not a sign of failure for biodegradable implants. Major
differences between permanent and biodegradable implants are seen in the progression of
the FBR. For instance, non-degradable permanent implants generally induce chronic
inflammation that is characterized by an ongoing presence of macrophages, FBGCs, an
extensive vascular network, and a low number of PMNs. In contrast, biodegradable implants
are infiltrated by FBGCs that phagocytose and completely degrade the biomaterial. Since
resorption of the biodegradable implant is the ultimate goal, and the regression of FBGCs is
seen with the resorption of the biomaterial, the FBGCs are not indicative of insufficient
biocompatibility and implant failure.
IV. STAGE-DEPENDENT IMPLANT-MEDIATED INFLAMMATION
The events in the FBR to a biodegradable implant are stage-dependent (Fig. 4). In other
words, the onset and progression of FBR is chiefly dependent on the implant’s physical
surface cues and attributes, 68 and is independent of the implant’s biodegradability.
Specifically, the absorbed protein layer that coats the implant’s surface is responsible for
much of the acute cellular events.69 However, over time, the protein coat is continuously
changing and the implant begins to degrade via hydrolysis, or enzymatic attack,
subsequently allowing for bone tissue regeneration.39 Thus, the resolution of the FBR is
essentially dictated by the degradation profile and products of the biodegradable implant.
The following section will discuss the events and factors involved in FBR resolution, as well
as methods that have previously been utilized to mitigate factors that may possibly lead to
the implant’s failure.
V. LONG-TERM EVENTS OF BIODEGRADABLE IMPLANT-ASSOCIATED
FBR
The eagerness to utilize biodegradable implants has been constrained by early reports of
FBRs and the resulting short-term complications. However, long-term FBR events, whether
beneficial or detrimental, are important variables to elucidate. The focus of this section is on
biodegradable implants, specifically, factors that contribute to FBRs, as well as the long-
term consequences that a non-specific FBR has on the implant and surrounding tissue. Some
noted outcomes include toxicity and chronic inflammation as a result of degradation
products, fibrous capsule formation, and bone tissue osteolysis. Ultimately, there have been
a series of documented long-term effects of biodegradable implants, but the principal finding
in many studies is that there are limited or unsignificant associated long-term effects with
biodegradable implants.16,70–74
V.A. Implant Degradation
The degradation process of biodegradable polymers generally occurs in two phases. During
the first phase, polymers go through a chain scission process. Consequently, the molecular
weight of the material is decreased, leading to a loss of mass and mechanical strength. The
second phase is characterized by particulate formation through implant breakdown, which,
subsequently, are engulfed by macrophages and removed.75 These phases appear to begin
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with the presence of FBGCs at the biomaterial’s surface. An unstirred microenvironment is
developed at the tissue-implant interface, at which FBGCs release degradation enzymes and
reactive oxygen species begin to biodegrade the polymer. The chemistry of the biomaterial
surface also dictates the rate of degradation and determines its biological impact.76 Factors
that affect the degradation of a polymeric implant include the implant material and its
crystallinity, implant geometry, site implantation, and the sterilization method used prior to a
surgical intervention. 75 In vivo degradation of PLGA-based polymers has been shown to
depend strongly on the ratio of monomers found in the co-polymers. For instance, PLGA
50:50 has been shown to have a half-life of approximately 3 weeks, while PLGA 85:15 has a
half-life of approximately 12 weeks.77
Despite numerous beneficial attributes, biodegradable polyesters (ie, poly(lactide) (PLA),
poly(glycolide) (PGA), poly(lactide-co-glycolide) (PLGA)) have not yet been adopted
globally in clinical settings. FBRs caused by acidic by-products of the implant and the
variable tissue response to degradation rates have been well documented. For instance, as
PLGA degrades, lactic acid and glycolic acid monomers are released in the surrounding
tissue. These monomers are later oxidized to pyruvic acid and eventually metabolized in the
Kreb cycle. When the release of organic acids over-whelms the system, bone can start to
demineralize. Nair and Schug demonstrated this clinically with solid PLGA implants, as
they observed a decline in the radiodensity of bone tissue surrounding solid PLGA implants
in patients.78
The resulting acidic environment also has a profound effect on the cytokine profiles of
inflammatory and endothelial cells surrounding the implants. It has been demonstrated that
the decrease in pH alters the amount of vascularization incorporated in a biomaterial long
after implantation. Further analysis has shown that osteoblasts, which are responsible for the
release of VEGF during healing, generated significantly less VEGF under acidic
conditions.79 In addition, polymeric implants with fast degradation times can also alter the
amount of blood vessel formation and implant integration. In an in vivo study with mouse
models, Sung et al. demonstrated that PLGA implants, with a fast degradation rate, display a
significantly lower density of cells expressing CD31, an endothelial cell specific marker,
two to four months post-implantation. This resulted in less angiogenesis and decreased bone
cell recruitment when compared to the relatively slow degradation of poly e-caprolactone
(PCL) implants.80
The rate of polymer degradation is directly related to the associated long-term FBR of a
biodegradable implant. A fast rate of biomaterial breakdown can overwhelm the local
scavenging mechanisms in the body and cause a more se vere FBR. In a large clinical study
that included over 2000 patients in Finland, scientists observed a decrease in the rate of FBR
from 5.3% of patients to 0.2% (1 out of 491 patients), when the fast degrading PGA
implants were replaced by relatively slow degrading PLA implants.2 The response to
degradation can vary from a mild reaction to a painful, erythematous papule over the
implant. More severe cases result in osteolytic implant failure requiring surgical
debridement and removal. Slower degradation provides an environment where the
scavenging mechanisms can cope with the removal of breakdown products. In clinical trials
that involve a myriad of polymeric orthopedic devices, the timing of adverse events can
occur from two weeks to six months after implantation (Ambrose and Clanton 2004).
Current efforts in biodegradable polymer synthesis aim to resolve the response caused by
rapid degradation and particulate formation, by developing polymer types with longer
degradation times, such as PCL, and less or no acidic degradation products, such as HAP
composites.
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V.B. Osteolysis
Osteolysis can be described as a change in the normal homeostatic state of bone that results
in an increase in bone resorption and the inappropriate breakdown of bone matrix.
Commonly associated with disease processes, osteolysis can appear secondary to a FBR. It
is likely that an osteolytic FBR is due to non-specific activation of bone resorption by the
hydrolyzed debris, as well as activation of macrophages through polymeric particles. The
release of mediators (ie, interleukins, prostaglandins) activates osteoclasts that may then
shift the balance of bone remodeling toward bone resorption.
In addition to particle-cell interactions between polymeric debris and osteoclasts, the
degradation rate of the polymeric implant may also play a role in osteolysis. Compared to
polylactides (PLAs), fast reabsorbable polyglycolides (PGAs) have a higher incidence of
adverse tissue reactions that lead to osteolytic FBRs. Supporting this assertion, a clinical
study involving PGA implants reported significant tissue reactions with sinus formation in
107 out of 2037 patients, while only one out of 491 patients treated with PLLA implants had
an osteolytic FBR.81,82 An additional factor that contributes to osteolysis is the placement of
the biodegradable implant in relation to bone. It is likely that intraosseous locations have
different rates of debris clearance, neovascularization and tissue replacement than
extraosseous locations, and therefore, a variable biological response is presented with
various biodegradable implants.81 This may explain why the osteolytic changes associated
with intraosseous PGA fixation implants can be characterized as an expected reaction, as
opposed to a complication. These mild osteolytic changes probably have no effect on
fracture healing or the static properties of the bone, unless a certain level is exceeded.83
Symptoms of osteolysis can range from no pain to joint swelling. A typical FBR with
osteolysis presents as a painful, fluctuating papule, located over the implant. If left
untreated, the papule usually bursts, and reveals a discharging sinus. More specifically,
osteolytic FBRs to biodegradable polyglycolide fixation devices have been documented to
cause sinuses that discharge polymeric debris (Fig. 5).82 The characteristic appearance of a
nonbacterial inflammatory sinus that may occur after reduction and internal fixation of a
bimalleolar fracture using PGA screws is shown in Fig. 5a, along with a radiograph of
osteolytic lesions that resulted after a trimalleolar fracture repair using PGA screws in Fig.
5b. Histologically, FBGCs surrounding polymeric particles of various sizes are often
observed in these cases. For instance, a histopathological slide taken 4.8 years after a
bimalleolar fracture repair with PLLA screws shows FBGCs surrounding polymeric
particles of various sizes is seen in Fig. 5c. The biopsy typically shows a uniform picture of
a non-specific inflammatory FBR.
To our knowledge, there has not been any literature comparing the prevalence of osteolysis
between biodegradable and permanent implants. Osteolysis, however, may also occur as a
result of permanent implants undergoing aseptic loosening and other impediments that
reduce the longevity of the implant. Although there have been documented osteolytic FBRs
for biodegradable implants, the number of cases are decreasing as more knowledge is
acquired about polymeric biocompatibility. Currently, scientists are working to improve the
biocompatibility of biodegradable implants to limit reactions that result in osteolysis.
V.C. Fibrotic Encapsulation
Fibrosis is essentially disorganized tissue regeneration. It originates from an increase in the
production of collagen I and III, fibronectin, and proteoglycans due to TGF-β
overproduction from the progression phase. These elements combine intra- and
intermolecularly, leading to the formation of collagen bundles. In addition, a concurrent
decrease in matrix degrading proteases, and an up-regulation of protease inhibitors by TGF-
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β, leads to an environment where ECM formation dominates. Under the influence of TGF-β
and PDGF released from macrophages, fibroblast-like cells differentiate into myofibroblasts
and proliferate (Fig. 2). Although myofibroblasts are important in wound healing, they are
also active producers of fibrotic tissue and aid in capsule shrinking during the resolution of
the FBR.40
Biodegradable polyester implants induce a fibrotic walling-off phenomenon after
implantation. However, there have been conflicting reports as to whether the implantation of
biodegradable implants leads to a host FBR similar to that of permanent implants with
respect to fibrotic encapsulation of the implant. For example, in a rabbit study comparing the
performance of PLA and PGA screws to metallic screws, the polyester screws were shown
to be inert with no significant difference in long-term biocompatibility.16 In another study
comparing the tissue response to PGA, polydioxanone (PDA), polylevolactide, and stainless
steel pins, scientists determined that all exhibit non-specific walling-off in cancellous bone
of distal rabbit femurs (Fig. 6).84 Some studies, however, have found fibrotic tissue
surrounding the implant that may be associated with the implant’s degradation. Pihlajamäki
et al. observed fibrotic tissue formation accompanying the degradation process of PLLA
screws, while no fibrous tissue was visible at the tissue-implant interface of the metallic
screws. However, as time elapsed and the screws degraded, the walling-off phenomenon
terminated, demonstrating the fibrosis to be related to the PLLA screw implants’
degradability.85
The walling-off phenomenon has been a major concern to the success of implants. While the
fibrotic encapsulation serves to reduce the inflammatory process, it also restricts
angiogenesis and nutrient supply that may result in implant failure during osteointegrative
processes.39 Neovascularization, which is essential to wound healing and bone regeneration
during polymeric degradation, may be inhibited by the fibrotic encapsulation. Also, the
fibrous cap confines the implant and prevents it from reacting with the surrounding tissue.86
Ultimately, this can alter the length of polymer degradation and functional tissue formation.
V.D. Sarcoma
A foreign-body sarcoma is a tumor that developed without a chemical carcinogenic
substance acting as a main cause or an adjuvant. Sarcomas have been a documented event
following the implantation of biodegradable implants. Based on increasing evidence, it
appears that the cause of these sarcomas is not the chemical content of the biodegradable
polymer, but instead is related to the implant’s form and size, length of implantation, and
degree of inflammation. For example, incidence of foreign body-induced sarcomas is higher
with implants with little tissue reaction, while tumor formation is inhibited with chronic
inflammation. These reactions have been seen with PLA implants, which have slow
degradation rates and a sarcoma incidence level as high as 80% in rats. It is important to
note, however, the incidence of sarcomas in the clinical setting has been extremely scarce.
For instance, it has been reported that foreign body-induced sarcomas have been observed in
only 50 cases out of millions,87 while it was also reported that no sarcoma cases have been
observed in association with craniofacial implants made with biodegradable polymers in
humans.88 Thus, implant-induced sarcomas may be species-dependent, and not related to the
actual implant.
VI. IMPLANT-ASSOCIATED FACTORS THAT INFLUENCE FBR
It is well established that the biomaterial’s physical properties and degradation profile
modulate the host FBR and inflammation, and ultimately, determine the fate of the implant
and bone regeneration (Fig. 7). Ideally, as the implant degrades, bone formation and
resolution of the FBR will occur. A clear understanding of how various biomaterial factors
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influence FBR and interactions with host cells is critical for the fabrication of a host-friendly
biomaterial that will elicit the least detrimental FBR, and optimal bone tissue regeneration
and integration.
VI.A. Implant Geometry
Implant geometry plays a crucial role in the acute stages of the FBR. Implant geometry
includes the gross geometry (ie, macrostructure), surface geometry (ie, microstructure or
microtopography), and internal geometry (ie, porosity and mean pore size). These factors are
perhaps the most important in determining the implant surface-bone tissue interface and,
thus, biocompatibility in vivo.39
The overall geometry of the implant may significantly affect the implant’s biocompatibility
if it causes irritation of the surrounding tissue. Implant structures with sharp angles provoke
the greatest inflammatory response, with high numbers of inflammatory cells and cellular
enzyme activity around implant.89 If too much irritation is caused, premature degradation
may occur and lead to implant failure. Furthermore, implant microtopography influences the
FBR in several aspects. For example, it directs the degree of the initial fibrin peri-implant
matrix upon which osteogenic and inflammatory cells must migrate. Microtopography also
affects the actual cell behavior, including adhesion, morphology, migration, orientation, and
differentiation.38,69 It has been suggested that topographical changes result in alterations in
the distribution of forces on a cell, resulting in a change in cell behavior.69 In addition,
implant surfaces of greater microtopography have increased surface area and, thus,
experience increased fibrinogen absorption and platelet adhesion.37,38,90,91 As mentioned
previously, platelets play an important role in the activation and progression of the FBR.
Platelets activated on microtextured candidate implant surfaces will upregulate neutrophils
to a greater extent than platelets activated on smoother implant surfaces.91 Increased
inflammatory responses have also been observed on implants with roughened surfaces, in
comparison to smooth surfaces, which involved increased macrophage and FBGC
numbers.92–95 The ability of roughened surfaces to increase platelet activation results in
heightened density gradients of cytokines and growth factors through which inflammatory
and osteogenic cells enter the transient fibrin matrix. As a result, microtopography also
directly influences osteoconduction and osteointegration. Increased osteogenic cells are
attracted to roughened implant surfaces, at which they have the ability to begin synthesizing
de novo bone. Thus, there is a direct correlation between implant surface roughness and
amount of bone formation at the bone-implant interface.96–101 For instance, titanium
implants with surfaces that have undergone a large-grit sandblast or acid etching
demonstrated a significantly higher extent of boneimplant interface than titanium implants
that had decreased roughness in vivo (ie, electropolished, medium-grit sandblasted and
plasma sprayed).96 Thus, the transient fibrin matrix, which is related to the surface
roughness, is critical for osteogenic and inflammatory cell migration to the implant surface,
and acts as a prelude to contact osteogenesis. The importance of this is observed as the
process of implant wetting prior to implantation is not practiced often, since this is expected
to dilute the implantcontacting fibrin and compromise osteogenic cell migration to the
implant surface.91
Recent bone tissue engineering efforts have also demonstrated that internal structure of the
biodegradable porous implant (ie, scaffold) influences the FBR and tissue regeneration. Pore
structure is determined by average pore size, distribution, geometry, and interconnectedness
within the implant.102 Generally, porous, in comparison to solid, implants result in a more
loosely packed and more vascularized surrounding capsule and, thus, improved permeability
for increased nutrient infiltration.40 Therefore, recent efforts were to identify the optimal
pore-sized scaffolds that will allow for the highest bone ingrowth and neovascularization. It
was concluded that three-dimensional scaffolds with higher porosity and pore sizes are
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associated with greater the bone ingrowth in vivo.103 This notion is well supported by the
lack of reports demonstrating enhanced osteogenesis in scaffolds with low pore sizes.
Furthermore, scaffolds must have direct and extensive surface contact between the implant
and host bone for osteoconduction, which can be achieved through increased porosity and
pore size that would allow for bone tissue ingrowth.39 A porosity of at least 80 to 90% and a
pore size of at least 300 μm are recommended for improved bone formation and
neovascularization. 39,103 Coincidently, 300 μm is also the average diameter of a human
osteon, which is the fundamental structural unit of bone. Deviation from this optimal range
of 300 μm pore diameter result in decreased vascularization, osteoblast attachment,
differentiation and proliferation, and ultimately, bone formation.104 The significance of
vascularization in constructs for bone regeneration is observed as scaffolds with small pores
limit oxygen transport (ie, hypoxia) and induce osteochondral formation before
osteogenesis, while large pores that are well-vascularized lead to direct osteogenesis.105
Thus, fulfillment of geometric specifications is critical to obtain optimal bone regeneration.
VI.B. Implant Surface Chemistry: Wettability
Surface wettability is a crucial implant surface characteristic to examine since it may be the
initial parameter affecting protein absorption at the implant surface. Water is commonly
believed to be the first molecule to contact biomaterials upon implantation, since water is
abundant and is also a small and agile molecule, only about 0.25 nm in the longest
dimension. A widely accepted definition of wettability states that hydrophobic surfaces have
contact angles greater than 65° (pure water adhesiontension (τ°< 30 dyn/cm), whereas,
hydrophilic (ie, more wettable) surfaces have contact angles less than 65°(τ°> 30 dyn/
cm).106
Although it is generally accepted that hydrophobic surfaces thermodynamically favor the
adsorption of proteins from the surrounding aqueous environment upon implantation, a
mechanism of enhanced cell response on hydrophilic surfaces may be due to the difference
in the array of absorbed proteins.107 Hydrophilic surfaces have been shown to preferentially
adsorb vitronectin, prothrombin, factors VII, IX and X, and activate complement via
covalent bonding of C3b to free OH and NH3 on the implant surface.36,37,47 On the other
hand, when hydrophobic surfaces are exposed to blood plasma, they bind certain
coagulation factors, such as factor V, fibrinogen, and fibronectin.36,37 Hydrophobic surfaces
induce strongly irreversible adsorption, thereby leading to the denaturation of the protein’s
native conformation and bioactivity, and reduced cell-adhesive function.37,107–110 Cell
functions, including proliferation, require reorganization of the surface-absorbed proteins,
which is largely impaired on more hydrophobic surfaces due to the tight and irreversible
binding.111 Thus, the ability of absorbed proteins to retain their functionality on hydrophilic
surfaces may contribute to the improved cell responses.
The previously accepted dogma states that hydrophobic surfaces inhibit cellular adhesion,
while hydrophilic surfaces promote cellular adhesion. This notion has been used to
rationalize why materials, such as titanium and HAP, which are hydrophilic, are able to
integrate with bone. However, numerous studies have reported discrepancies when detailing
whether hydrophobic or hydrophilic surfaces promote cell adhesion. For example, in one
study, surface energy appeared to be of more importance initially, with hydrophobic
surfaces producing faster cell activation and differentiation than hydrophilic.112 Also, very
hydrophobic materials such as PTFE (contact angles of 105°–116°) inhibit cellular
adhesion.63 This observed cellular inhibition might have resulted from conformational
changes of the adsorbed proteins, such that ligand moieties needed for integrin binding and
cellular adhesion became inaccessible. In contrast, hydrophilic materials such as tissue
culture polystyrene (TCPS) are known to support cellular adhesion. Furthermore, in a study
comparing a PLGA/PVA scaffold with hydrophilic properties, to another PLGA scaffold
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with hydrophobic properties, cell adhesion and growth faired better on the PLGA/PVA
scaffolds. 113 Other hydrophilic materials that present highly hydrated surfaces (ie,
hydrogels, polyethylene oxide, pHEMA, PEO) create a substantial barrier to protein
adsorption and inhibit cellular adhesion.37
Interestingly, this feature of hydrophilic surfaces to display decreased cell adhesion has led
to the suggestion that hydrophilic surfaces have superior biocompatibility, and could
potentially be used to reduce the FBR. Specifically, hydrophilic surfaces have been
associated with limited adhesion of monocytes and macrophages, an increased level of
apoptosis in adhered monocytes and macrophages, and a reduced amount of macrophage
fusion into FBGCs.65,114–116 Hydrophilic surfaces have also been associated with adherent
cells producing statistically greater amounts of cytokines and chemokines, such as IL-10,
IL-1β, IL-6, IL-8, and MIP-1β, than their hydrophobic counterparts.117,118 Also, with
increasing time, production of the antiinflammatory cytokine IL-10 increased, whereas
IL-1β, IL-6, and IL-8 decreased and MIP-1β was relatively constant. The inverse trend of
decreased cell adherence and increased cell activation/activity can be attributed to the
increased release of certain cytokines in cells undergoing apoptosis.119
There are many conflicting reports on the affect of surface wettability on protein absorption,
as well as cell adhesion and activity. Even when comparing single cell types, there is
inconsistent data, indicating that there is definitely interplay between various surface
characteristics, including wettability, charge, topography, and porosity. In addition, it is
difficult to accurately study the effect of changing one factor, such as wettability, since there
is a strong inter-relationship between the various characteristics of a surface (ie, changing
one property almost inevitably changes others as well).68 For example, increasing
hydophobicity of a sample may be associated with changes in the chemical groups expressed
on the implant surface, and thus the surface free energy. It is also important to note that cell-
material interactions are governed by the many various surface properties, and one property
is not single-handedly responsible for the resulting FBR.
Although the effect of hydrophilicity/hydrophobicity has been quite controversial and
inconsistent in experimental data, it is now well accepted that very hydrophilic and
hydrophobic surfaces are not good for cell attachment. Rather, surfaces with moderate
wettability are able to adsorb a proper amount of proteins, and at the same time preserve
their natural conformation, resulting in positive cell response. Because most synthetic
biodegradable polymers are hydrophobic, including the polyesters, extensive efforts have
thus been devoted towards increasing the biomaterial’s hydrophilicity, such as surface
modifications before cell seeding.37 This concept of moderately hydrophilic material surface
being able to induce “good” cell interaction, although widely accepted, requires further
detailed studies to gain a better understanding of the optimal hydrophilicity/hydrophobicity
equilibrium for a specific cell’s behavior on a specific material.
VII. EFFORTS TO MITIGATE FBR
Much effort has been devoted to altering the surface of biomaterials in order to overcome or
reduce the FBRs associated with implantation, while also enhancing integration and
biomechanical properties of bone.23 With increased understanding of these properties, we
can improve the tolerance of implants. In the following section, we will review how these
surface changes can mitigate the FBR, as well as provide a beneficial component to bone
tissue integration.
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VII.A. Hydrophilicity/Hydrophobicity of Implant Surface
Biomaterial surfaces display distinct surface wettability characteristics that play a significant
role in biological host responses, namely cellular adhesion and FBGC formation. As
previously mentioned, studies suggest that hydrophilic implant surfaces may decrease FBR
via various mechanisms. Namely, implants with hydrophilic surfaces are associated with
limited macrophage adhesion, increased apoptosis in adhered macrophages, and reduced
macrophage fusion to FBGCs. This associated decrease in FBR may be attributed to the
promotion of apoptosis, which, unlike necrosis, does not provoke cell inflammation, as the
sealed bodies do not release inflammation-inducing intracellular fragments. Also,
hydrophilic implant surfaces result in a decreased production of pro-inflamma tory cytokines
(ie, IL-1 and IL-6) and increased anti-inflammatory cytokines (ie, IL-10) by adherent
macrophages.117 Hydrophilic implant surfaces are well tolerated by the immune system, and
result in reduced fibrinogen adsorption and interaction with fibrotic cells, thereby decreasing
implant-induced fibrosis.120 Thus, hydrophilic, apoptosis-inducing biomaterials can
decrease the number of adhered macrophages and formation of FBGCs, and thereby
effectively reduce or alter the release of cytokines, reactive oxygen species, degradative
enzymes, and fibrosis that compromise the biological response.117
As a result of these observations, efforts have been made to increase the hydrophilicity of
biomaterials, since many biodegradable polymers are hydrophobic. Various proposed
methods include (i) plasma treatments that introduce polarized groups (ie, hydroxyl,
carboxyl, amino, and sulfate groups) to material surfaces by using different reaction gases
(ie, air, carbon dioxide, sulfur dioxide, ammonia, organic compounds), (ii) graft
copolymerization by introducing radicals or peroxide groups onto hydrophilic polymers via
ozone oxidation, x-rays, electron beam and laser treatments, and (iii) photo-oxidation to
universally introduce peroxide groups by immersing the materials in hydrogen peroxide
while under UV radiation.107 Also, in order to create more protein adsorption-resistant
surfaces, the implants were coated with polyethylene glycol,121–124 and other hydrophilic
polymers, including poly(2-hydroxyethyl methacrylate), poly(N-isopropyl acrylamide),
poly(acrylamide), and phosphoryl choline-based polymers.34,125
VII.B. Biomimetic Surface Modifications
Optimal bone regeneration occurs when the implant mimics the native bone ECM as closely
as possible. The structure of the biodegradable scaffold should serve as a synthetic replica
and act as a temporary ECM, in order to support cell attachment and guide three-
dimensional bone tissue formation.126 Since the two main components of bone ECM are
Type I collagen fibrils and HAP crystals, each of which are less than 50 nanometers in
diameter, nanostructures for bone regeneration have gained much attention. 127–129 Nano-
featured scaffolds include nanofibrous scaffolds, and scaffolds with nano-modified surface
topography and composition. For example, nanofibrous scaffolds composed of chitosan, a
biodegradable and nontoxic natural polymer, have been demonstrated to achieve complete
bone regeneration with no inflammatory signs. It has been observed that macrophages and
lymphocytes enhance bone regeneration in rabbit calvarial defect model after four weeks
post-implantation.130
Surface modifications used to improve implant osteocompatibility and tissue integration
include HAP and calcium phosphate (CaP) coatings, which are heavily investigated due to
their similarity to bone mineral, as well as cell adhesion molecules with the Arg-Gly-Asp
sequence, which promote cell attachment (Table 2).35 Appleford et al. demonstrated
enhanced osetocompatibility of HAP scaffolds coated with micro-size and nano-size HAP
with significant bone ingrowth and blood vessel infiltration compared to the control at 12
weeks.131 In addition, Hunt et al. demonstrated significantly more new bone formation and
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decreased inflammatory response when comparing composite HAP/PLLA interference
screws to PLLA screws in a large animal ACL reconstruction model.132 Likewise, PLGA
scaffolds coated with CaP resulted in a significantly lower inflammatory response, as
determined by histomorphometrical analysis of FBGCs, in comparison to non-coated PLGA
scaffolds at 8-weeks post-implantation.133 Thus, through the incorporation or coating of
implants with biomimetic agents, increased bone regeneration and decreased FBR may be
attained.
VII.C. Incorporation of Anti-Inflammatory Agents and Growth Factors
The inclusion of anti-inflammatory agents in the implants provides a direct approach to
controlling the FBR upon implantation. Though many of the described approaches have
mostly been applied to permanent implant surfaces, they can be further adopted for use with
biodegradable implants as well.
Anti-inflammatory glucocorticoids, such as dexamethasone (DEX), have been used due to
their ability to stop the formation of pro-inflammatory mediators (prostaglandins,
leukotrienes). In a study involving DEX-loaded PLGA microspheres/PVA hydrogel
composites, significantly lower quantities of neutrophils and macrophages, and fibrosis were
observed when compared to control samples loaded with no DEX, after 4 weeks of
implantation (Fig. 8).134 DEX-loaded composites were similar to the normal host tissue,
with only a few neutrophils, and no evidence of a fibrous cap until day 21. However, once
the drug was depleted, neutrophil levels increased. This study, along with numerous others,
demonstrated the effect of DEX release on FBR.86,135–141
Other anti-inflammatory agents previously utilized to modulate macrophage behavior and
reduce levels of pro-inflammatory cytokines upon implantation of biodegradable implants
include prednisolone,142 α-melanocyte stimulating hormone (α-MSH),143 PAR1 peptide
thrombin receptor agonist (PAR1-AP),144 and tetracycline.145 Scientists have also coated
non-degradable implants with heparin and synthetic thrombin receptor agonist to shorten the
inflammatory FBR, since they functions to bind to regulators of coagulation and
complement activation.80,146–153 Also, anti-inflammatory coatings previously reported to
reduce neutrophil recruitment and FBR upon implantation of non-biodegradable implants
include superoxide dismutase mimetics,154 interleukin-1 receptor antagonist,155
curcumin,156–158 and vitamin E.159
VIII. CONCLUSIONS & FUTURE DIRECTIONS
Biodegradable implants are emerging as an effective alternative to permanent implants
because of their capacity to mimic the physical properties of metals, while reducing the need
of a secondary surgical intervention for implant removal. Advancement, however, of these
novel implants requires a thorough consideration of the biological response to the implant
material, as well as their degradation characteristics. Upon implantation of biodegradable
implants, the short-term reactions of the surrounding tissue are similar to the acute
interactions seen with permanent implants. A series of events occur at the tissue-implant
interface that proceeds from protein adsorption and mast cell histamine release, to monocyte
recruitment and foreign body giant cell formation. As for long-term effects, biodegradable
implants, ideally, should show excellent biocompatibility and be able to exist in the body
while evoking minimal to no immune responses. However, long-term inflammatory events
of biodegradable implants are initiated by the degradation of the polymer, and heighten
especially when the host’s by-product and particle clearing mechanisms are overwhelmed.
The main challenge for development of biodegradable implants is to moderate the long-term
FBR. Although a tolerable level of inflammation is vital to the healing process, chronic
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stimulation of the immune system can negatively impact the function of the implant and its
degradation profile. Because the surface chemistry can impact the behavior of immune cells,
surface modifications have been studied to lessen the host’s response. This has been
accomplished by engineering ways to reduce protein adsorption, alter the wettability of the
biomaterial, and even provide a template for regulated delivery of anti-inflammatory agents.
Future work should continue to enhance our understanding of the cell-implant interaction,
and seek to further ameliorate the FBR by manipulating various biodegradable implant
characteristics.
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FIGURE 1.
Biodegradable orthopedic implants. (A) Screws, plates, rods and tacks, commonly utilized
for fracture fixation and meniscal repair (reprinted from Ciccone et al. 200128). (B) Plates
and cages for spinal repair. (C) Porous scaffolds for bone tissue engineering [reprinted from
Journal of the American Academy of Orthopaedic Surgeons, vol. 9, no. 5, pp. 280–8,
Ciccone WJ, Motz C, Bentley C, Tasto JP. Bioabsorbable implants in orthopaedics: new
developments and clinical applications. Copyright (2001), with permission from Elsevier].
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FIGURE 2.
Schematic illustration of biodegradable material-induced inflammation.39,47,63,91,92
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FIGURE 3.
Histological analysis of a subcutaneous mouse model of nylon mesh biomaterial
implantation was performed by analysis of tissue sections of the implant and lesion area at 4
weeks post-implantation (reprinted from Higgins et al.200952). (A, B) Immunohistochemical
staining of macrophages and FBGCs in implant tissue sections. Tissue sections were stained
for (A) F4/80 and (B) CD11b. (C, D) Immunohistochemical staining of (C) B220 for B cells
and (D) CD3 for T cells in implant tissue sections. Arrows indicate stained lymphocytes. (E)
The distances between stained CD3, B220 cells or FBGCs and the nearest implant surface.
(F) Adhesion cell density. (G) Percentage of macrophage fusion [reprinted from the
American Journal of Pathology, vol. 175, no. 1, pp. 161–70, Higgins D, Basaraba R,
Hohnbaum A, Lee E, Grainger D, Gonzalez-Juarrero M. Localized immunosuppressive
environment in the foreign body response to implanted biomaterials. Copyright (2009), with
permission from Elsevier].
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FIGURE 4.
Stage-dependent implant-mediated inflammation. Factors that mediate short-term
inflammatory responses to biodegradable implants are independent of their biodegradability
characteristics, and instead dependent on trauma-induced inflammation and implant surface
characteristics. Long-term inflammation induced by these implants, however, is largely
affected by their biodegradation.165
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FIGURE 5.
(A) A foreign-body reaction to biodegradable fixation devices made of polyglycolide
resulted in a sinus discharging polymeric debris. Observed sinus 11 weeks postoperative on
the lateral side of the left ankle of a 43-yr-old man with a bimalleolar fracture that was
treated by open reduction and internal fixation using polyglycolide screws. (B)
Anteroposterior radiograph of osteolytic lesions (asterisks) at the implant tracks in a 45-yr-
old woman with a trimalleolar fracture of the right ankle that was treated by open reduction
and internal fixation using polyglycolide screws, 9 weeks postoperative. (C) The
characteristic histopathological picture of a non-specific foreign-body reaction to
biodegradable implants. Polymeric particles of various sizes (asterisks) are seen surrounded
by foreign-body giant cells. Masson-Goldner stain, original magnification 350x [reprinted
from Biomaterials, vol. 21, no. 24, pp. 2615–21, Bostman O, PihlajamaÅnki H. Clinical
biocompatibility of biodegradable orthopaedic implants for internal f xation: a review.
Copyright (2000), with permission from Elsevier].
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FIGURE 6.
Comparison of non-specific walling-off phenomenon resulting from permanent and
biodegradable implants. Schematic drawing of the operated femur (A,B). The distal end of
the femur shows the polymer implant (1) and metallic implant (2) in the drill hole (A), and
the distal half of the femur shows the bioabsorbable (1) and metallic pin (2) placement in the
intramedullary canal in the anteroposterior view (B). In the histologic specimens, a walling-
off response was observed for both bioabsorbable and metallic pins (C–F). Fibrous tissue
and bone trabecula outlining the PDS pin at 3 weeks (C). A bone rim is seen outlining the
metallic wire at 12 weeks (D). A fibrous tissue zone surrounds the PGA pin at 24 weeks (E).
Thin bone trabecula outlining the PLLA pin at 52 weeks (F). * Implant channel; black
arrows, bone; arrowheads, fibrous tissue; white arrow, PDS particles. Masson-Goldner
trichrome staining. (reprinted from Pihlajamäki et al. 2010.16)
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FIGURE 7.
Biodegradable orthopedic implant-induced inflammation, and the parallel tissue
regeneration and wound-healing paradigm. Characteristic histopathological picture of a non-
specific foreign-body reaction to biodegradable implants include (A) acute inflammation
marked by neutrophils (green arrows); (B) chronic inflammation marked by multinucleated
giant cells (dark green arrows), fibrosis (light blue arrows), and mixed inflammatory cells
(black arrow); and (C) fibrosis around the implant (yellow arrows) stained with Masson’s
trichrome stain (collagen is stained blue). These images were obtained from samples
generated by implanting PVA hydrogel/PLGA microsphere composites (marked by *) into
the subcutaneous tissue of rats after (A) 3, (B) 30, and (C) 60 days. Bar = 100 μm134
[reprinted from the Journal of Diabetes Science and Technology, vol. 2, no. 6, pp. 1003–15,
Onuki Y, Bhardwaj U, Papadimitrakopoulos F, Burgess D. A review of the biocompatibility
of implantable devices: current challenges to overcome foreign body response. Copyright
(20089), with permission from Diabetes Technology Society].
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FIGURE 8.
Pharmacodynamic changes in representative tissue sections after subcutaneous implantation
of PLGA microsphere/PVA hydrogel composites (HC) containing dexamethasone at (A)
day 7 and (B) day 30 post-implantation. (C) Untreated normal tissue. Hematoxylin and eosin
stain, HC = hydrogel composite [reprinted from the Journal of Diabetes Science and
Technology, vol. 2, no. 6, pp. 1003–15, Onuki Y, Bhardwaj U, Papadimitrakopoulos F,
Burgess D. A review of the biocompatibility of implantable devices: current challenges to
overcome foreign body response. Copyright (20089), with permission from Diabetes
Technology Society].
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TABLE 1
Summary of Biodegradable Orthopedic Implants
Biodegradable Material Type of Implant Properties that Influence FBR Adverse Event
In Clinical Use
Poly(α-esters): PGA
PLLA, PDLLA, PLLAHA, PLLA-
TCP
PLGA
PDO
PGA-TMC
Pins, Screws, Plates, Rods,
Tacks, Suture anchors, Spine
cages, and Scaffolds
Acidic degradation (Lactic/
Glycolic Acids)
Hydrophobic
Implant fragmentation &
particle generation
Fluid accumulation
Sinus formation
Swelling
Osteolysis
Synovitis
Cyst formation (human
studies)
Collagen
Collagen-HA
Collagen-TCP
Injectable gels and Foams for
BTE
Biological None
Calcium Phosphate
TCP, HA
Bone cements
Scaffolds
Slow degradation
Particle generation
None (rabbit study)
Under Development
Poly(α-esters): PCL, PHB, PHV,
PHBV
Scaffolds Acidic degradation
Hydrophobic
Slow degradation
None (human study)
Poly(propylene fumerate) Scaffolds, Injectable gels Acidic degradation (Fumaric
acid, Propylene glycol)
Minimal inflammatory
response (rabbit study)
Poly(ester urethanes) Injectable gels and Scaffolds Neutral degradation (Ammonia,
Carboxylic acids)
Enzymatic degradation
No acute inflammation (mice
study)
Polyphosphazenes PNEG, PNEA,
PNEPhA
Scaffolds Neutral degradation (Ammonia
+ Phosphate)
Tunable hydrophobicity
Less inflammatory response
compared to PLGA (rat study)
Natural Polymers: Chitin &
Chitosan, Starch
Injectable gels
Scaffolds
Natural and biological
enzymatic degradation
Chronic inflammation (rabbit
study)
PGA – polyglycolide; PLLA – poly(L)lactide; PDLLA – poly(DL)lactide; TCP – tri-calcium phosphate; HA – hydroxyapatite; PLGA –
poly(lactide-co-glycolide); PDO – polydioxanone; PGA-TMC - poly(glycolide-co-trimethylene carbonate); PCL – poly(caprolactone); PHB –
poly(hydroxybutyrate); PHV - poly(hydroxyvalerate); PHBV – poly(hydroxybutyrate-co-hydroxyvalerate); PNEG – poly[bis(ethyl
glycinato)phosphazene]; PNEA – poly[bis(ethyl alanato)phosphazene]; PNEPhA – poly[bis(ethyl phenylalaninato) phosphazene].
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TABLE 2
Agents Reported in the Literature to Alleviate the Host FBR
Agent Implant Type Mechanism of Delivery Selected References
Dexamethasone (Dex) Injectable PLGA based colloidal gel Dex-loaded gels Wang et al. 2010135
Dex/PLGA microspheres Dex-loaded microspheres Zolnik and Burgess 2008,
Hickey et al. 2002, Patil
et al. 2004, Bhardwaj et
al. 2007, Kim et al.
2003 136–139,141
PLGA nanosphere-coated microspheres Dex-loaded nanospheres Park et al. 2011160
Porous PLGA scaffolds Dex incorporated into PLGA Kim and Martin 2006140
Prednisolone PLGA microspheres Prednisolone-loaded microspheres Khaled et al. 2010142
α-Melanocyte Stimulating
Hormone (α-MSH)
Poly-l-glutamic acid (PGA) Covalently coupled to PGA Fioretti et al. 2010161
PAR1 peptide thrombin
receptor agonist (PAR1- AP)
Lactic and glycolic acid copolymer
scaffold
PAR1-AP encapsulation Dugina et al. 2004144
Tetracycline Composite PLA/PLGA dispersed in a
bioceramic matrix (Osteosynt)
Tetracycline-loaded composites Pataro et al. 2007145
VEGF PLGA microsphere/PVA hydrogel
composites loaded with VEGF & Dex
VEGF-loaded microspheres Patil,
Papadimitrakopoulos and
Burgess 2007162
Arg-Gly-Asp (RGD) peptide PLGA microspheres Surface modification Park et al. 2010163
Hydroxyapatite (HA) Bioactive glass HA-coating Xie et al. 2010164
PLLA-HA screws HA incorporation Hunt and Callaghan
2008132
HA scaffolds coated with nano-sized HA
or microsized HA
HA-coating Appleford et al. 2009131
Calcium phosphate (CaP) Macroporous PLGA/CaP composite
scaffolds coated with CaP
CaP coated Lickorish et al. 2004133
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